- GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
-
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula II.
- -
-
-
- GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
-
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I), as follows: wherein R1, R2, R4, W, X, Y, and G, are defined herein.
- -
-
-
- GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
-
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (III); wherein R1c, R2C, R4C, Wc, Yc, Zc and Gc, are defined herein.
- -
-
-
- HETEROCYCLICALLY SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINONES AND THEIR USE
-
The present application relates to novel heterocyclically substituted 6-(trifluoromethyl)pyrimidin-4(3H)-one derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular, renal, inflammatory and fibrotic diseases.
- -
-
Paragraph 0211
(2017/02/24)
-
- HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE
-
The present application relates to novel heterocyclically substituted 6-(trifluoromethyl)pyrimidin-4(3H)-one derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of cardiovascular, renal, inflammatory and fibrotic diseases.
- -
-
Paragraph 0503
(2016/10/04)
-
- Anti-ulcer pyridyloxy derivatives, their preparation and uses
-
Compounds of formula (I): STR1 [wherein: R1 is a cyclic amino group, or a dialkylamino group; R2 a group of formula --NHCHR3 R4 wherein R3 and R4 are each alkyl aryl or aralkyl, or together form a cycloalkyl group, or R2 is an aromatic heterocyclic group, or a group of formula --B--S(O)m --R5 wherein R5 is a substituted alkyl group, or an aromatic heterocyclic group; B is an alkylene or alkylidene group; m is 0, 1 or 2; A is a group of formula --CH=CH-- or --(CH2)n --, where n is 1, 2 or 3]; and salts thereof have valuable anti-ulcer activity.
- -
-
-